ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Clinicopathological insights and prognostic implications of DEK in association with apoptosis-regulating factors in ovarian cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- All hands on DEK: structural insights into a unique histone modifier and chromatin remodeler.Epigenetics & chromatin · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeOvarian cancer is one of the most common gynecologic malignancies of the present era. Dysregulation of apoptosis is considered as one of the most important factors for malignant transformation. DEK is a ubiquitous protein, and its downregulation induces apoptosis by altering BCL-2, BAX, and CASPASE-3 expressions. This study illuminates the cumulative clinical usefulness of DEK and related apoptotic proteins.
methodsA total of 119 patients were enrolled during 2021-2023. Demographic and clinicopathological data were recorded at presentation, and the follow-up was done till August 2024. Tissue samples were analyzed using immunohistochemistry and real-time PCR. A paired t test assessed gene expression between normal and malignant tissues of different treatment strategies. The crosstab was performed to find the association of DEK, BCL-2, BAX, and CASPASE-3 with clinicopathological features. Pearson's correlation was used to predict the association of DEK with other apoptotic factors. Survival and hazard risk were evaluated using log-rank and Cox regression.
resultsThe mean age of OC patients was 47.61 ± 12.5 years, presented with advanced stage (90.7%) and grade (85.3%). Most of them were post-menopausal (68.08%) and had unhygienic (76.5%) regular menstrual cycles (89.1%), and also experienced early pregnancy (61.8%). Some of these factors are related to a hazard risk (HR > 1). DEK and apoptotic proteins were upregulated in OC than in normal (p ≤ 0.01). DEK was positively correlated with BCL-2, BAX, and CASPASE-3, at both mRNA and protein levels, and only BAX showed significance in both (p ≤ 0.05). All the selected genes are independent risk factors for survival of OC (HR > 1), but only DEK and CASPASE-3 were significantly associated with poor survival (p ≤ 0.05).
conclusionsDysregulation of DEK, CASPASE-3, and BAX/BCL-2 is associated with poor overall survival. Further, this study highlights the correlation between DEK and key apoptotic regulators, emphasizing the critical role of DEK in OC prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.